Who are TLK286 HCl for injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Drug: Carfilzomib + Lenalidomide + Dexamethasone, Drug: Carfilzomib + Dexamethasone, Bortezomib, Melphalan, Prednisone, VBMCP/VBAD/Velcade, lenalidomide, bortezomib and dexamethasone, R2: Lenalidomide + ixazomib maintenance.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tlk286-hcl-for-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TLK286 HCl for injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TLK286 HCl for injection (TLK286 HCl for injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proteasome inhibitor. Area: Oncology.

phase 3 Proteasome inhibitor 20S proteasome Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TLK286 HCl for injection (TLK286 HCl for injection) — Telik. TLK286 HCl for injection is a proteasome inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TLK286 HCl for injection TARGET	TLK286 HCl for injection	Telik	phase 3	Proteasome inhibitor	20S proteasome
Drug: Carfilzomib + Lenalidomide + Dexamethasone	Drug: Carfilzomib + Lenalidomide + Dexamethasone	Amgen	marketed	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
Drug: Carfilzomib + Dexamethasone	Drug: Carfilzomib + Dexamethasone	Amgen	marketed	Proteasome inhibitor + corticosteroid combination	20S proteasome (carfilzomib); glucocorticoid receptor (dexamethasone)
Bortezomib, Melphalan, Prednisone	Bortezomib, Melphalan, Prednisone	Fondazione EMN Italy Onlus	phase 3	Proteasome inhibitor + alkylating agent + corticosteroid combination	20S proteasome (bortezomib); DNA (melphalan); glucocorticoid receptor (prednisone)
VBMCP/VBAD/Velcade	VBMCP/VBAD/Velcade	PETHEMA Foundation	phase 3	Proteasome inhibitor	20S proteasome
lenalidomide, bortezomib and dexamethasone	lenalidomide, bortezomib and dexamethasone	National Heart, Lung, and Blood Institute (NHLBI)	phase 3	Combination therapy: immunomodulatory agent, proteasome inhibitor, and corticosteroid	Multiple targets: cereblon (lenalidomide), 20S proteasome (bortezomib), glucocorticoid receptor (dexamethasone)
R2: Lenalidomide + ixazomib maintenance	R2: Lenalidomide + ixazomib maintenance	University of Leeds	phase 3	Immunomodulatory agent + proteasome inhibitor combination	Cereblon (lenalidomide); 20S proteasome (ixazomib)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proteasome inhibitor class)

Millennium Pharmaceuticals, Inc. · 2 drugs in this class
Meletios A. Dimopoulos · 1 drug in this class
National Cancer Institute (NCI) · 1 drug in this class
PETHEMA Foundation · 1 drug in this class
Pfizer · 1 drug in this class
Shilpa · 1 drug in this class
Telik · 1 drug in this class
European Myeloma Network B.V. · 1 drug in this class
University of Arkansas · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TLK286 HCl for injection — Competitive Intelligence Brief. https://druglandscape.com/ci/tlk286-hcl-for-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing